Targeted pill plus chemo for relapsed T-cell lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a new targeted pill (golidocitinib) combined with two standard chemotherapy drugs (gemcitabine and oxaliplatin, known as GemOx) for people with peripheral T-cell lymphoma that has come back or not responded to previous treatment. The goal is to see if this combination is safe and works better than current options.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old.
- You must have been diagnosed with peripheral T-cell lymphoma (PTCL) that has come back or not improved after at least one previous treatment.
- You need to have at least one tumor that can be measured on a CT or MRI scan.
- Your overall health should be fairly good (able to do light activities).
- Your blood counts, kidney, and liver function must be within acceptable ranges.
- You must not have certain other cancers, serious heart problems, or active infections.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of a targeted drug (golidocitinib) with either a chemotherapy liposome or another targeted drug (chidamide) for people with peripheral T-cell lymphoma that has come back or stopped responding to treatment. The goal is to see if the combination works better than current options.
This trial tests a new drug called golidocitinib added to standard chemotherapy (CHOP) for people newly diagnosed with certain types of T-cell lymphoma. It aims to see if the combination works better than CHOP alone.
This trial tests a new drug, golidocitinib, against a standard treatment chosen by your doctor for peripheral T-cell lymphoma that has come back or not responded to prior therapy. The goal is to see which approach works better for patients.
This trial tests a combination of two drugs, golidocitinib and pomalidomide, for people with a type of lymphoma called peripheral T-cell lymphoma (PTCL) that has come back or stopped responding to prior treatment. The goal is to see if this combination can help shrink tumors or slow the disease.
This trial is testing several new drug combinations for people with peripheral T-cell lymphoma that has come back or not responded to treatment. It aims to find new options that may work better.
This trial compares a new targeted drug combined with standard chemotherapy and an immunotherapy drug against the standard chemo-immunotherapy alone, for people with advanced or non-nasal NK/T-cell lymphoma who haven't been treated yet. The goal is to see if adding the targeted drug improves outcomes.
Hear when a new Peripheral T-cell Lymphomas (PTCL) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.